ACOR Financial Facts
Total other expense (net): -4.54MOperating income (loss): -5.47M
See Full Income Statement
Total assets: 1.32B
Current portion of convertible notes payable: 1.13M
See Full Balance Sheet
Acorda Therapeutics, Inc. (ACOR) Earnings
|
Expand Research on ACOR
Next EPS Date | N/A | EPS Growth Rate | -139.7% *Last Qtr. |
---|---|---|---|
Average EPS % Beat Rate | -188.2% | Revenue Growth Rate | +63.1% *Last Qtr. |
Average % Move 1-Wk after EPS | -8.4% | Normal Earnings Time | After Close |
Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
---|---|---|---|---|---|---|---|---|---|---|---|
11/1/10 | Q310 | $0.31 | -$0.13 | +$0.44 | N/A | N/A | N/A | Details | |||
2/17/11 | Q410 | $0.09 | $0.17 | -$0.08 | $66.8M | $64.26M | N/A | Details | |||
5/5/11 | Q111 | $0.08 | $0.18 | -$0.10 | $61.29M | $64.25M | N/A | Details | |||
8/1/11 | Q211 | $0.19 | $0.12 | +$0.07 | $65.28M | $66.29M | N/A | Details | |||
11/4/11 | Q311 | $0.40 | $0.73 | -$0.33 | $93.03M | $90.78M | N/A | Details | |||
2/16/12 | Q411 | $0.45 | $0.18 | +$0.27 | $72.64M | $69.16M | N/A | Details | |||
5/3/12 | Q112 | $0.36 | $0.18 | +$0.18 | $71.25M | $70.95M | N/A | Details | |||
7/31/12 | Q212 | $0.27 | $0.12 | +$0.15 | $75.66M | $72.55M | N/A | Details |